Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181275 | 0.78 | MEN1 (0.47) | MEN1GAARAB9AKMT2ADRD3 | |
| SCHEMBL1512469 | 0.72 | CA12 (0.46) | MEN1GAARAB9AKMT2ADRD3 | |
| SCHEMBL873778 | 0.72 | CASP3 (0.52) | MEN1RAB9AKMT2ADRD3KDM4E | |
| SCHEMBL20979820 | 0.71 | CASP3 (0.50) | MEN1GAARAB9AKMT2ADRD3 | |
| SCHEMBL20680187 | 0.71 | MEN1 (0.41) | MEN1GAARAB9AKMT2ADRD3 | |
| SCHEMBL25212256 | 0.68 | NPSR1 (0.54) | KDM4EHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24618686 | 0.67 | MEN1 (0.39) | MEN1GAARAB9AKMT2ADRD3 | |
| SCHEMBL11665542 | 0.67 | CA12 (0.43) | MEN1KMT2ADRD3ALDH1A1CASP3 | |
| SCHEMBL92102 | 0.67 | CYP1B1 (0.67) | MEN1KMT2ADRD3KDM4ESMN1; SMN2 | |
| SCHEMBL29969387 | 0.67 | CYP1B1 (0.67) | MEN1KMT2ADRD3KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6803198-B2 | COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6322987-B1 | FOR TREATING AN ANIMAL HAVING A DISEASE CHARACTERIZED BY UNDESIRED PRODUCTION OF PROTEIN | ISIS PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0983291-A4 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6166188-A | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6111085-A | COMPOUND HAVING AT LEAST ONE NUCLEOSIDE WITH A DERIVATIVE AT THE 2'-O OR 3'-O POSITION; FOR IMPROVED PROPERTIES AND CONJUGATION OF FUNCTIONAL MOIETIES SUCH AS STEROIDS, REPORTER MOLECULES, REPORTER ENZYMES, LIPOPHILIC MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0983291-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998011123-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | MEN1 2452/4885GAA 462/4885RAB9A 4667/4885 |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | MEN1 2452/4885GAA 462/4885RAB9A 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.